These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Lancet; 1992 Mar; 339(8796):753-70. PubMed ID: 1347801 [TBL] [Abstract][Full Text] [Related]
3. Thrombolytic therapy in Europe: current status. Vahanian A Eur Heart J; 1996 Sep; 17 Suppl E():21-7. PubMed ID: 11824000 [TBL] [Abstract][Full Text] [Related]
4. The role of perfusion data. Rapaport E Eur Heart J; 1990 Aug; 11 Suppl F():10-4. PubMed ID: 2121487 [TBL] [Abstract][Full Text] [Related]
6. [Thrombolytic drugs in acute myocardial infarct]. Ambrosioni E; Degli Esposti D Cardiologia; 1991 Dec; 36(12 Suppl 1):395-402. PubMed ID: 1841796 [TBL] [Abstract][Full Text] [Related]
7. Intravenous thrombolytic therapy in myocardial infarction: an analytical review. Shammas NW; Zeitler R; Fitzpatrick P Clin Cardiol; 1993 Apr; 16(4):283-92. PubMed ID: 8458108 [TBL] [Abstract][Full Text] [Related]
8. New developments in thrombolytic therapy. Collen D; Gold HK Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372 [TBL] [Abstract][Full Text] [Related]
9. Thrombolysis: the need for a critical review. Monrad ES J Am Coll Cardiol; 1991 Nov; 18(6):1573-8. PubMed ID: 1939963 [TBL] [Abstract][Full Text] [Related]
10. [t-PA in thrombolytic therapy of acute myocardial infarct]. Rutsch W; Schmutzler H Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690 [TBL] [Abstract][Full Text] [Related]
11. Creation of the recombinant tissue plasminogen activator (rt-PA) image and its influence on practice habits. Sherry S; Marder VJ J Am Coll Cardiol; 1991 Nov; 18(6):1579-82. PubMed ID: 1939964 [TBL] [Abstract][Full Text] [Related]
12. Thrombolytic therapy for acute myocardial infarction. Are inclusion criteria too stringent? Handlin LR; Vacek JL Postgrad Med; 1994 Mar; 95(4):77-82. PubMed ID: 8121861 [TBL] [Abstract][Full Text] [Related]
14. Thrombolytic therapy in acute myocardial infarction. Paspa PA; Movahed A Am Fam Physician; 1992 Feb; 45(2):640-8. PubMed ID: 1739049 [TBL] [Abstract][Full Text] [Related]
15. Is survival in acute myocardial infarction related to thrombolytic efficacy or the open-artery hypothesis? A controversy to be investigated with GUSTO. Bates ER Chest; 1992 Apr; 101(4 Suppl):140S-150S. PubMed ID: 1555479 [TBL] [Abstract][Full Text] [Related]
16. Safe use of thrombolysis in the elderly. Wittry MD; Thornton TA; Chaitman BR Geriatrics; 1989 Nov; 44(11):28-30, 33-6. PubMed ID: 2509296 [TBL] [Abstract][Full Text] [Related]
17. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. GUSTO investigators N Engl J Med; 1993 Sep; 329(10):673-82. PubMed ID: 8204123 [TBL] [Abstract][Full Text] [Related]
18. [Atenolol i.v. in the acute phase of AMI: the indications, contraindications and interactions with thrombolytic drugs in the GISSI-2 study. The GISSI-2 Researchers. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico]. Mafrici A; Mauri F; Maggioni AP; Franzosi MG; Santoro L; De Vita C G Ital Cardiol; 1995 Mar; 25(3):353-64. PubMed ID: 7642042 [TBL] [Abstract][Full Text] [Related]
20. ISIS-3 and GISSI-2: no survival advantage with tissue plasminogen activator over streptokinase, but a significant excess of strokes with tissue plasminogen activator in both trials. Collins R; Peto R; Parish S; Sleight P Am J Cardiol; 1993 May; 71(12):1127-30. PubMed ID: 8475887 [No Abstract] [Full Text] [Related] [Next] [New Search]